Pacific Marine Biotech

8 Church Street
First Floor
Torrington, Connecticut 06790

Phone: 959-901-4050
Website: http://pacificmarinebiotech.com

General Information:

Pacific Marine Biotech (PMB) founded in 2022 and headquartered in Torrington, Connecticut, with additional operations in Brisbane, Australia.

The company is focused on developing innovative, marine-derived therapies for difficult-to-treat cancers, particularly glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). Its lead investigational product, Immune12, is a proprietary complex biologic derived from marine organisms and designed to modulate immune response and exhibit potential anti-tumor activity.

Pacific Marine Biotech’s research program includes extensive preclinical studies, where Immune12 has demonstrated anti-cancer activity in vitro and in vivo, including tumor growth inhibition and a favorable safety profile in animal models.

Building on these findings, the company is advancing clinical development, including Phase 2 GBM 60 patient trials in Australia evaluating Immune12 in patients with high-grade gliomas. These studies aim to assess safety, efficacy, tumor response, and quality-of-life outcomes while supporting regulatory pathways toward FDA approval.

Through its integrated research and clinical strategy, PMB seeks to bring a novel, low-toxicity biologic therapy to patients with limited treatment options, leveraging marine biotechnology to address unmet needs in oncology.